ClinicalTrials.Veeva

Menu

Incidence of POPF in the Resection of the Left Pancreas With RFAT (RFATPancreas)

H

Hospital del Mar

Status

Unknown

Conditions

Benign Pancreas Tumor
Pancreatic Adenocarcinoma
Pancreas Cancer
Pancreas Neoplasm

Study type

Observational

Funder types

Other

Identifiers

NCT03570502
2017/7697/I

Details and patient eligibility

About

This study evaluates the impact of the Radiofrequency assisted transection on the rate of postoperative pancreatic fistula (POPF) after performing distal pancreatectomies, central pancreatectomies and pancreatic enucleation

Full description

Among the different methods for sealing the remaining pancreas, resection and sealing devices assisted by radiofrequency energy (RF) have been used, both in experimental studies and in clinical trials, in order to try to reduce the POPF rate. One of these devices is the Coolinside®, which is approved for this indication and is currently used in selected cases, at the Hospital del Mar, among other centers.

Although there are several published studies based on similar technology, the existing publications on the use of Coolinside® in the pancreas have been made in rat and pig animal models. In particular, the most recent study published by Dorcaratto et al. compares the Coolinside device vs. the mechanical stapler in porcine model when performing distal pancreatectomies. The results suggest that the Coolinside device was more efficient in the control of the POPF than the stapler with a POPF index of 12% vs. 36%.

Therefore, this study aims to obtain more clinical evidence about the use of Coolinside in pancreatic resections within a clinical context.

Enrollment

38 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with benign or malignant lesions of the pancreas
  • Subjected to distal, central pancreatectomy or enucleations of the left pancreas
  • Patients ASA (American Society of Anesthesiologists I-III
  • Open or laparoscopic approach.

Exclusion criteria

  • ASA ≥IV patients
  • Patients with limitrophic or neuroendocrine lesions

Trial contacts and locations

1

Loading...

Central trial contact

Ignasi Poves, Phd, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems